Short Interest in CalciMedica, Inc. (NASDAQ:CALC) Drops By 68.7%

CalciMedica, Inc. (NASDAQ:CALC) was the target of a large decrease in short interest in July. As of July 15th, there was short interest totalling 21,800 shares, a decrease of 68.7% from the June 30th total of 69,600 shares. Currently, 0.5% of the company’s shares are short sold. Based on an average trading volume of 37,100 shares, the days-to-cover ratio is currently 0.6 days.

Insider Activity at CalciMedica

In other CalciMedica news, Director Robert N. Wilson acquired 8,443 shares of the firm’s stock in a transaction on Thursday, June 27th. The stock was purchased at an average cost of $3.23 per share, for a total transaction of $27,270.89. Following the transaction, the director now owns 258,918 shares of the company’s stock, valued at approximately $836,305.14. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 53.30% of the stock is owned by insiders.

Institutional Trading of CalciMedica

An institutional investor recently raised its position in CalciMedica stock. BML Capital Management LLC lifted its position in CalciMedica, Inc. (NASDAQ:CALC) by 63.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 145,424 shares of the company’s stock after purchasing an additional 56,643 shares during the quarter. CalciMedica accounts for 0.3% of BML Capital Management LLC’s portfolio, making the stock its 29th largest position. BML Capital Management LLC owned about 2.56% of CalciMedica worth $416,000 at the end of the most recent reporting period.

Analysts Set New Price Targets

A number of research firms recently commented on CALC. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of CalciMedica in a report on Tuesday, July 9th. Oppenheimer raised their price target on shares of CalciMedica from $14.00 to $20.00 and gave the company an “outperform” rating in a report on Wednesday, July 10th. Finally, Singular Research raised shares of CalciMedica to a “moderate buy” rating in a research report on Friday, June 28th.

CalciMedica Stock Performance

CALC stock opened at $3.88 on Friday. The company has a 50-day moving average of $4.85 and a two-hundred day moving average of $4.76. CalciMedica has a 52-week low of $1.75 and a 52-week high of $8.38.

CalciMedica (NASDAQ:CALC) last issued its quarterly earnings results on Monday, May 13th. The company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.07. Equities analysts anticipate that CalciMedica will post -2.08 EPS for the current fiscal year.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.